4BB 4basebio PLC
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modifications within the DNA backbone; and Hermes, a nanoparticle platform. The company also provides custom pegRNA and sgRNA manufacturing; and nanoparticle formulation services. Its products are used in mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines, and non-viral delivery applications. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is headquartered in Cambridge, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About 4basebio (LON: 4BB)
›
4basebio (LON: 4BB) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 140 employees.
The shares were at 525.00 GBp on 19 November 2026, down 27.6% over 52 weeks.
Its market capitalisation is 100.70M GBP.
4basebio reports return on equity of -167.2% and revenue down 77.7% year over year.
Its debt exceeds its cash by 9.06M GBP, a debt-to-equity ratio of 1.65. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 1130.00 GBp is 115.2% above the current price.